Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Arcturus Therapeutics Holdings Inc
(NQ:
ARCT
)
18.05
+0.15 (+0.81%)
Streaming Delayed Price
Updated: 12:38 PM EST, Dec 4, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Arcturus Therapeutics Holdings Inc
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Match Group, Super Micro Computer And Some Other Big Stocks Moving Higher In Today's Pre-Market Session
November 02, 2022
U.S. stock futures traded slightly higher this morning. Here are some big stocks recording gains in today’s pre-market trading session.
Via
Benzinga
Arcturus Announces Collaboration with CSL to Develop and Commercialize Self-amplifying mRNA Vaccines
November 01, 2022
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Arcturus Therapeutics to Report Third Quarter 2022 Financial Results and Provide Corporate Update on November 9, 2022
October 26, 2022
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
BARDA Backs Arcturus' Influenza Vaccine Program
September 01, 2022
Via
Benzinga
Arcturus' COVID-19 Booster Shows Durability Against Omicron Variants
August 18, 2022
Via
Benzinga
4 Analysts Have This to Say About Arcturus Therapeutics
August 10, 2022
Within the last quarter, Arcturus Therapeutics (NASDAQ:ARCT) has observed the following analyst ratings:
Via
Benzinga
Recap: Arcturus Therapeutics Q2 Earnings
August 09, 2022
Arcturus Therapeutics (NASDAQ:ARCT) reported its Q2 earnings results on Tuesday, August 9, 2022 at 04:00 PM. Here's what investors need to know about the announcement.
Via
Benzinga
Micron, Charles River Laboratories And Some Other Big Stocks Moving Higher On Friday
September 30, 2022
U.S. stocks traded slightly higher, with the Nasdaq Composite gaining more than 80 points on Friday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
Arcturus Therapeutics to Attend the Following Investor Conferences
September 27, 2022
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
7 Small-Cap Stocks to Buy on the Dip or You’ll Be Kicking Yourself Later
September 22, 2022
With the market taking a dip and possibly poised to incur more red ink, these are the small-cap stocks to buy that appeal to contrarians.
Via
InvestorPlace
Arcturus Therapeutics to Attend the Following Investor Conferences
September 01, 2022
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Expert Ratings for Arcturus Therapeutics
May 10, 2022
Within the last quarter, Arcturus Therapeutics (NASDAQ:ARCT) has observed the following analyst ratings:
Via
Benzinga
Arcturus Announces $63.2 Million Award from the U.S. Government to Support Development of Self-amplifying mRNA Vaccine for Rapid Pandemic Influenza Response
August 31, 2022
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Arcturus Reports Durability Data Against Omicron Variants, Including BA.5, at Six-Month Timepoint Following Booster with ARCT-154 COVID-19 Vaccine
August 18, 2022
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For August 10, 2022
August 10, 2022
Via
Benzinga
Arcturus Therapeutics Announces Second Quarter 2022 Financial Update and Pipeline Progress
August 09, 2022
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Biotech Daily: Regulatory Setback For CorMedix, Mersana & GSK In Cancer Pact, BARDA Funding For Opioid Overdose Hopeful
August 09, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Arcturus Therapeutics to Report Second Quarter 2022 Financial Results and Provide Corporate Update on August 9, 2022
August 01, 2022
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
What 6 Analyst Ratings Have To Say About Arcturus Therapeutics
July 19, 2022
Over the past 3 months, 6 analysts have published their opinion on Arcturus Therapeutics (NASDAQ:ARCT) stock. These analysts are typically employed by large Wall Street banks and tasked with...
Via
Benzinga
Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
June 21, 2022
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
May 20, 2022
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
93 Biggest Movers From Yesterday
June 14, 2022
Gainers Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) shares surged 126% to close at $14.96 on Monday after the company announced initial data from the pivotal FIREFLY-1 trial of tovorafenib in...
Via
Benzinga
70 Stocks Moving In Monday's Mid-Day Session
June 13, 2022
Gainers Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) shares jumped 110% to $13.93 after the company announced initial data from the pivotal FIREFLY-1 trial of tovorafenib in relapsed pediatric...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 11, 2022
May 11, 2022
Upgrades
Via
Benzinga
70 Biggest Movers From Friday
May 31, 2022
Gainers Avadel Pharmaceuticals plc (NASDAQ: AVDL) shares climbed 133.6% to close at $2.50 on Friday. Avadel Pharmaceuticals shares dipped 68% on Thursday after announcing new FDA request for...
Via
Benzinga
Arcturus Therapeutics Announces First Quarter 2022 Financial Update and Pipeline Progress
May 09, 2022
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Arcturus Therapeutics's Earnings Outlook
May 06, 2022
Arcturus Therapeutics (NASDAQ:ARCT) is set to give its latest quarterly earnings report on Monday, 2022-05-09. Here's what investors need to know before the announcement. Analysts estimate that...
Via
Benzinga
Arcturus Reports Three-Month Durability Results From ARCT-154 COVID-19 Booster Trial
May 05, 2022
Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) provided updated data from its Phase 1/2 booster clinical trial showing the durability of antibody response with ARCT-154 for at least three months...
Via
Benzinga
Arcturus Reports Strong Three-Month Durability Results from ARCT-154 Booster Trial
May 05, 2022
From
Arcturus Therapeutics Holdings Inc.
Via
Business Wire
Arcturus Therapeutics to Report First Quarter 2022 Financial Results and Provide Corporate Update on May 9, 2022
April 27, 2022
From
Arcturus Therapeutics
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.